drugset / Trial / NCT03384914
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Phase 2
Active not recruiting
119 enrolled
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival). Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and a booster phase.
Timeline
- Start
- 2018-02-19
- Primary completion
- 2025-12-22
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | DC vaccine | Vaccine | — | Other |
| Comparator | pUMVC3-IGFBP2-HER2-IGF1R | Vaccine | — | Other |